Robert S. Alter, MD

Robert Alter, MD comments on the use of prognostic models for determining risk status and informing treatment options in patients with RCC.

Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.

Experts open their discussion on RCC by reviewing the clinical scenario of a patient with favorable-risk disease who is treated with the TKI/IO regimen of lenvatinib and pembrolizumab.

Drs. Dutcher, Mourad, and Ennis have provided an excellent review of current and potential future treatments of renal cell carcinoma (RCC); we would like to highlight some salient points from a urologic perspective.